WO2011161245A3 - Polymorphs of febuxostat - Google Patents

Polymorphs of febuxostat Download PDF

Info

Publication number
WO2011161245A3
WO2011161245A3 PCT/EP2011/060630 EP2011060630W WO2011161245A3 WO 2011161245 A3 WO2011161245 A3 WO 2011161245A3 EP 2011060630 W EP2011060630 W EP 2011060630W WO 2011161245 A3 WO2011161245 A3 WO 2011161245A3
Authority
WO
WIPO (PCT)
Prior art keywords
febuxostat
relates
present
polymorphs
crystalline form
Prior art date
Application number
PCT/EP2011/060630
Other languages
French (fr)
Other versions
WO2011161245A2 (en
Inventor
Andreas Hotter
Ulrich Griesser
Verena Adamer
Christoph Langes
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43033242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011161245(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Priority to ES11727454.8T priority Critical patent/ES2553574T3/en
Priority to EP15181097.5A priority patent/EP2977372B1/en
Priority to PL11727454T priority patent/PL2585445T3/en
Priority to US13/702,077 priority patent/US8946441B2/en
Priority to CA2802937A priority patent/CA2802937C/en
Priority to EP11727454.8A priority patent/EP2585445B1/en
Priority to DK11727454.8T priority patent/DK2585445T3/en
Publication of WO2011161245A2 publication Critical patent/WO2011161245A2/en
Publication of WO2011161245A3 publication Critical patent/WO2011161245A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Abstract

The present invention relates to crystalline form I of Febuxostat as well as to pharmaceutical compositions comprising crystalline form I as an active pharmaceutical ingredient. Furthermore the present invention relates to a further polymorphic form of Febuxostat designated as form II and to a novel solvate of Febuxostat. The present invention also relates to methods of making crystalline form I, form II and the novel solvate of Febuxostat.
PCT/EP2011/060630 2010-06-25 2011-06-24 Polymorphs of an active pharmaceutical ingredient WO2011161245A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES11727454.8T ES2553574T3 (en) 2010-06-25 2011-06-24 Polymorphs of a pharmaceutical active substance
EP15181097.5A EP2977372B1 (en) 2010-06-25 2011-06-24 Polymorphs of febuxostat
PL11727454T PL2585445T3 (en) 2010-06-25 2011-06-24 Polymorphs of an active pharmaceutical ingredient
US13/702,077 US8946441B2 (en) 2010-06-25 2011-06-24 Polymorphs of an active pharmaceutical ingredient
CA2802937A CA2802937C (en) 2010-06-25 2011-06-24 Polymorphs of febuxostat
EP11727454.8A EP2585445B1 (en) 2010-06-25 2011-06-24 Polymorphs of an active pharmaceutical ingredient
DK11727454.8T DK2585445T3 (en) 2010-06-25 2011-06-24 Polymorphs of An active pharmaceutical component.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10167344.0A EP2399911B1 (en) 2010-06-25 2010-06-25 Polymorphs of Febuxostat
EP10167344.0 2010-06-25

Publications (2)

Publication Number Publication Date
WO2011161245A2 WO2011161245A2 (en) 2011-12-29
WO2011161245A3 true WO2011161245A3 (en) 2012-03-08

Family

ID=43033242

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/060630 WO2011161245A2 (en) 2010-06-25 2011-06-24 Polymorphs of an active pharmaceutical ingredient

Country Status (7)

Country Link
US (1) US8946441B2 (en)
EP (3) EP2399911B1 (en)
CA (1) CA2802937C (en)
DK (2) DK2399911T3 (en)
ES (2) ES2553584T3 (en)
PL (2) PL2399911T3 (en)
WO (1) WO2011161245A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553584T3 (en) * 2010-06-25 2015-12-10 Sandoz Ag Febuxostat polymorphs
CN103396378B (en) * 2013-07-29 2015-06-10 杭州朱养心药业有限公司 Stable febuxostat crystal
CZ27857U1 (en) 2014-12-12 2015-02-23 Zentiva, K.S. Formulation containing febuxostat solid solution

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1020454A1 (en) * 1998-06-19 2000-07-19 Teijin Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
US20050043375A1 (en) * 2002-03-28 2005-02-24 Michio Iwai Solid preparation containing single crystal form
CN101648926A (en) * 2009-07-09 2010-02-17 石药集团欧意药业有限公司 Febuxostat crystal form and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395381T3 (en) 2009-06-10 2013-02-12 Teva Pharmaceutical Industries Ltd. Crystal forms of Febuxostat
CN101817801A (en) * 2009-08-12 2010-09-01 北京红惠新医药科技有限公司 Preparation method of new crystal form K of 2-(3-cyano-4-isobutoxy)-4-methyl-5-thiazole formic acid and other crystal forms
ES2553584T3 (en) 2010-06-25 2015-12-10 Sandoz Ag Febuxostat polymorphs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1020454A1 (en) * 1998-06-19 2000-07-19 Teijin Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
US20050043375A1 (en) * 2002-03-28 2005-02-24 Michio Iwai Solid preparation containing single crystal form
CN101648926A (en) * 2009-07-09 2010-02-17 石药集团欧意药业有限公司 Febuxostat crystal form and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERNSTEIN: "Polymorphism in Molecular Crystals", 2002, CLARENDON PRESS, Oxford, ISBN: 0198506058, XP002608621 *
See also references of EP2585445A2 *

Also Published As

Publication number Publication date
CA2802937A1 (en) 2011-12-29
EP2585445A2 (en) 2013-05-01
PL2399911T3 (en) 2016-01-29
EP2399911A1 (en) 2011-12-28
CA2802937C (en) 2020-02-25
US20130137734A1 (en) 2013-05-30
EP2977372B1 (en) 2019-05-08
PL2585445T3 (en) 2016-01-29
EP2977372A1 (en) 2016-01-27
WO2011161245A2 (en) 2011-12-29
ES2553574T3 (en) 2015-12-10
EP2399911B1 (en) 2015-08-19
DK2585445T3 (en) 2015-09-07
ES2553584T3 (en) 2015-12-10
EP2585445B1 (en) 2015-08-19
DK2399911T3 (en) 2015-09-07
US8946441B2 (en) 2015-02-03

Similar Documents

Publication Publication Date Title
WO2010114405A3 (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
WO2012042371A3 (en) Pharmaceutical composition
WO2012088038A3 (en) Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
WO2010092090A3 (en) Novel salts of sitagliptin
WO2012122011A3 (en) Amino-quinolines as kinase inhibitors
WO2011012816A3 (en) Pharmaceutical formulation
WO2010139981A3 (en) Processes for preparing crystalline forms of dasatinib
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
WO2012088124A3 (en) Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
WO2012015681A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto
WO2011157722A3 (en) Solid ivabradine-containing composition
WO2012101011A3 (en) New aryl-benzocycloalkyl amide derivatives
WO2012015999A3 (en) Process for the preparation of imatinib mesylate
WO2012137227A3 (en) Solid forms of antiretroviral compounds and anti-oxidative acids, processes for preparation and pharmaceutical compositions thereof
WO2013128379A3 (en) Crystalline polymorphic forms of linagliptin
WO2011139886A3 (en) Preparation of febuxostat
WO2010129636A3 (en) Lenalidomide polymorph
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2011135581A3 (en) Pharmaceutical compositions of dronedarone
WO2011023954A3 (en) Polymorphic forms of manidipine
WO2011161245A3 (en) Polymorphs of febuxostat
WO2011156045A3 (en) Tablet formulation of ezatiostat
WO2012015687A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11727454

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011727454

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2802937

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13702077

Country of ref document: US